Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy
Anticancer Research · 2025
DOI: 10.21873/anticanres.17745 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Anticancer Research, 2025. Verfasst von Takafumi Fukui und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, B7-H1 Antigen, Lung Neoplasms, Immune Checkpoint Inhibitors.
Abstract (Originalsprache)
BACKGROUND: The optimal treatment for advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of 1-49% remains unknown. Further stratification by PD-L1 TPS may lead to optimization of treatment. PATIENTS AND METHODS: We conducted a multicenter, retrospective, observational study to compare nivolumab and ipilimumab with/without chemotherapy (dual-therapy group) and chemotherapy with a single-agent immune checkpoint inhibitor (ICI) (single-therapy group) as the first-line therapy for advanced NSCLC with a PD-L1 TPS of 1-49%. The primary endpoint was overall survival in the propensity score-matched population. RESULTS: A total of 139 patients were enrolled; 113 in the single- (81.3%) and 26 in the dual- (18.7%) therapy groups. In the population with PD-L1 TPS of 1-20%, after propensity score-matching was performed, the median overall survival was 12.0 months for the single-therapy group, but was not reached for the dual-therapy group (p=0.022). The median progression-free survival was 6.9 and 11.5 months, respectively (p=0.02). In the population with PD-L1 TPS of 21-49%, after propensity score-matching, the median overall survival was not reached for the single-therapy group, but was 9.0 months for the dual-therapy group (p=0.04), whilst corresponding median progression-free survival was 8.3 and 4.1 months (p=0.087). CONCLUSION: The results of this study suggest that in patients with NSCLC, the optimal treatment regimen may differ between those with PD-L1 TPS of 1-20% and 21-49%; moreover, nivolumab and ipilimumab-based therapy may be more effective than chemotherapy with a single-agent ICI for treating advanced NSCLC with ultra-low PD-L1 expression, particularly in those with a PD-L1 TPS of 1-20%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Division of Respiratory Medicine, Kakogawa Central City Hospital, Kakogawa, Japan.
- Division of Respiratory Medicine, Akashi Medical Center, Akashi, Japan.
- Division of Respiratory Medicine, Hyogo Prefectural Awaji Medical Center, Sumoto, Japan.
- Division of Respiratory Medicine, Takatsuki General Hospital, Takatsuki, Japan.
- Division of Respiratory Medicine, Nishikobe Medical Center, Kobe, Japan.
Zitieren
APA
Fukui, T., Hori, S., Hatakeyama, Y., Kiriu, T., Matsumura, K., Miwa, N., Katsurada, M., Okuno, K., Yoshimura, S., & Tachihara, M. (2025). Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy. Anticancer Research. https://doi.org/10.21873/anticanres.17745
Vancouver
Fukui T, Hori S, Hatakeyama Y, Kiriu T, Matsumura K, Miwa N, et al. Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy. Anticancer Research. 2025. doi:10.21873/anticanres.17745
BibTeX
@article{Fukui2025,
author = {Fukui, Takafumi and Hori, Suya and Hatakeyama, Yukihisa and Kiriu, Tatsunori and Matsumura, Kanoko and Miwa, Nanako and Katsurada, Masahiro and Okuno, Keiko and Yoshimura, Sho and Tachihara, Motoko},
title = {Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17745}
}
EUVIMED